Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Bored. Waiting. Here is some playing with data to look at.

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Sep 24, 2023 4:12pm

272 Views

Post# 35651373

RE:RE:Bored. Waiting. Here is some playing with data to look at.

In a recent interview Dr. Neil Shore is enthusiastic about the significance of the approval of Adstiladrin for BCG-unresponsive NMIBC patients, it had a durable complete response at 24 months of around 20%.

"This is really great, because for these patients, who have CIS, who again, are BCG- unresponsive, what one would be potentially contemplating, or having the discussion with their patients, is potential cystectomy""

TLD1433 PDT could end up achieving a 40% durable CR - double that of Adstiladrins 20% rate

I only hope that experts like Dr. Shore will be as enthusiastic about TLD1433 PDT when it is finally approved as it may help twice as many patients save their bladders

https://www.audacy.com/podcast/onclive-on-air-07a35/episodes/s8-ep17-fda-approval-insights-nadofaragene-firadenovec-in-bcg-unresponsive-nmibc-105c7?action=AUTOPLAY_FULL&actionContentId=201-5acb8eb0-9088-402c-962f-70dd24ddafcd

Eoganacht wrote: Nice. Thanks.

The statement "100% of CR at 360 stay that way at 450" is particularly gratifying.

It bodes well for Ruvudar PDTs durable response at 24 months and beyond, particularly when compared with competing treatments, some of whuch experience significant declines in efficacy after 12 months in the absence of continuous treatments.

From the latest MD&A: "Patients who achieve CR at 90 days and continue to demonstrate a CR response at 450 days will be followed to assess the duration of their CR beyond 450 days."

DJDawg wrote: I like playing around with patterns. Here is a URL pic of what I made recently as there is nothing else to do for now.

I took the swimmers plot and other data to generate a table to see some patterns.

-What do the under-treated 12 look like?

-What do the patients who start CR look like?

-What do the patients who start IR look like?

-What do the patients who start NR look like?

I tend to focus on the pure CR's that stay that way as they are different than the rest.

Love any corrections or feedback.

https://i.postimg.cc/tgpKJXvh/TLT-data-discussion.png